Ed Keystone

3.3k total citations
25 papers, 572 citations indexed

About

Ed Keystone is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Ed Keystone has authored 25 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Rheumatology, 7 papers in Immunology and 6 papers in Genetics. Recurrent topics in Ed Keystone's work include Rheumatoid Arthritis Research and Therapies (19 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Systemic Lupus Erythematosus Research (6 papers). Ed Keystone is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (19 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Systemic Lupus Erythematosus Research (6 papers). Ed Keystone collaborates with scholars based in Canada, United States and United Kingdom. Ed Keystone's co-authors include Carl F. Ware, Bindee Kuriya, Joan M. Bathon, Paul Emery, Jie Han, M Bala, Marc D. Cohen, Joachim R. Kalden, E. William St. Clair and Ravinder N. Maini and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and The American Journal of the Medical Sciences.

In The Last Decade

Ed Keystone

25 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ed Keystone Canada	11	365	147	144	98	97	25	572
Lena Innala Sweden	7	520 1.4×	105 0.7×	77 0.5×	74 0.8×	62 0.6×	11	630
Eun Bong Lee South Korea	11	215 0.6×	151 1.0×	59 0.4×	70 0.7×	69 0.7×	14	509
Norifumi Sawamukai Japan	14	359 1.0×	267 1.8×	134 0.9×	103 1.1×	97 1.0×	25	672
Jean‐Frédéric Boyer France	10	323 0.9×	181 1.2×	54 0.4×	109 1.1×	39 0.4×	15	553
Liliana Morales Argentina	2	469 1.3×	134 0.9×	236 1.6×	45 0.5×	141 1.5×	2	625
Katarzyna Romanowska‐Próchnicka Poland	14	186 0.5×	230 1.6×	77 0.5×	142 1.4×	33 0.3×	37	644
Bozena Möller Sweden	9	678 1.9×	471 3.2×	72 0.5×	93 0.9×	60 0.6×	12	962
Regina Kurrasch United States	12	266 0.7×	188 1.3×	71 0.5×	59 0.6×	77 0.8×	21	534
Yeong-Wook Song South Korea	8	207 0.6×	89 0.6×	69 0.5×	80 0.8×	52 0.5×	13	382
M. C. Genovese United States	10	634 1.7×	228 1.6×	320 2.2×	53 0.5×	162 1.7×	38	842

Countries citing papers authored by Ed Keystone

Since Specialization

Citations

This map shows the geographic impact of Ed Keystone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ed Keystone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ed Keystone more than expected).

Fields of papers citing papers by Ed Keystone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ed Keystone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ed Keystone. The network helps show where Ed Keystone may publish in the future.

Co-authorship network of co-authors of Ed Keystone

This figure shows the co-authorship network connecting the top 25 collaborators of Ed Keystone. A scholar is included among the top collaborators of Ed Keystone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ed Keystone. Ed Keystone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rahman, Proton, Ed Keystone, D. Choquette, et al.. (2020). Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry. BMC Rheumatology. 4(1). 46–46. 10 indexed citations

Kuriya, Bindee, Orit Schieir, Marie‐France Valois, et al.. (2019). Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis. ACR Open Rheumatology. 1(9). 535–541. 9 indexed citations

Kuriya, Bindee, Marc D. Cohen, & Ed Keystone. (2017). Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential. Therapeutic Advances in Musculoskeletal Disease. 9(2). 37–44. 41 indexed citations

Kay, Jonathan, et al.. (2017). OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 76. 136–136. 2 indexed citations

Hitchon, Carol, Gilles Boire, Boulos Haraoui, et al.. (2016). Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. Lara D. Veeken. 55(10). 1751–1762. 28 indexed citations

Kremer, Joel M., Ed Keystone, Paul Emery, et al.. (2016). AB0390 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance To Anti-TNF Biologic Therapy. Annals of the Rheumatic Diseases. 75. 1038–1039. 7 indexed citations

Jacob, Binu, et al.. (2015). The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. Clinical Rheumatology. 35(3). 759–763. 30 indexed citations

Taylor, Peter C., Mark C. Genovese, Ed Keystone, et al.. (2014). A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1. Annals of the Rheumatic Diseases. 73. A31–A32. 10 indexed citations

Smolen, Josef S, D. Schlichting, K.L. Sterling, et al.. (2012). 12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Arthritis & Rheumatism. 64. 5 indexed citations

10.

Genovese, M. C., Ed Keystone, P. W. J. Taylor, et al.. (2012). 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.. Oxford University Research Archive (ORA) (University of Oxford). 64(10). 10 indexed citations

11.

Peterfy, Charles, Paul Emery, M. C. Genovese, et al.. (2012). Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.. Oxford University Research Archive (ORA) (University of Oxford). 8 indexed citations

12.

Keystone, Ed, Peter C. Taylor, Mark C. Genovese, et al.. (2012). LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 71. 152–153. 14 indexed citations

13.

Conaghan, Philip G., P. Emery, Mikkel Østergaard, et al.. (2011). Assessment of inflammation and damage by MRI in established RA patients with Methotrexate inadequate response receiving Golimumab: Results of the GO-FORWARD trial. Annals of the Rheumatic Diseases. 70. 2 indexed citations

14.

Keystone, Ed & Carl F. Ware. (2010). Tumor Necrosis Factor and Anti-Tumor Necrosis Factor Therapies. PubMed. 85(0). 27–39. 57 indexed citations

15.

Keystone, Ed. (2009). Clinical Implications of Understanding Radiographic Findings in Relation to Clinical Outcomes in Rheumatoid Arthritis. PubMed. 82(0). 11–16. 12 indexed citations

16.

Smolen, Josef S, Désirée van der Heijde, Paul Emery, et al.. (2008). Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Annals of the Rheumatic Diseases. 68(6). 823–827. 182 indexed citations

17.

Oene, Mark Van, Richard F. Wintle, Xiangdong Liu, et al.. (2005). Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis & Rheumatism. 52(7). 1993–1998. 100 indexed citations

18.

Devogelaer, Jean‐Pierre, Kalden, Paul Emery, et al.. (2004). Infliximab therapy leads to clinical and radiographic benefits in early rheumatoid arthritis patients receiving optimum methotrexate dose. Annals of the Rheumatic Diseases. 63. 293–293. 4 indexed citations

19.

Genovese, M. C., Roy Fleischmann, Ed Keystone, et al.. (2001). OP0121 Enbrel® (etanercept) vs. methotrexate (mtx) in early rheumatoid arthritis (era trial): two-year follow-up. Annals of the Rheumatic Diseases. 60. A483–A484. 15 indexed citations

20.

Keystone, Ed & W. Pruzanski. (1976). Immunochemical and physical studies of the Sia test. The American Journal of the Medical Sciences. 271(2). 151–157. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact